—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Rhythm Pharmaceuticals Inc (RYTM) — Technical state

As of 2026-11-03 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 41 out of 100 (momentum 48 · quality 21 · valuation 6), as of 2026-11-04.
  • Signal: Downtrend stack — Trades -10.3% vs the 50-day and -10.8% vs the 200-day average, 29.3% below the 52-week high and +16% off the 52-week low; a death cross printed 2 sessions ago. Computed from daily closes. (as of 2026-11-03)
  • Trend: Rhythm Pharmaceuticals Inc trades 10.3% below its 50-day and 10.8% below its 200-day moving average. (as of 2026-11-03)

Rhythm Pharmaceuticals develops treatments for rare genetic forms of obesity linked to faults in the melanocortin-4 receptor pathway that controls hunger. Its approved drug, setmelanotide, treats several of these inherited conditions, and it is testing further MC4R-pathway compounds, including an oral pill and a longer-acting injectable, in patients with related genetic and hypothalamic obesities.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the RYTM overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Downtrend stack

Trades -10.3% vs the 50-day and -10.8% vs the 200-day average, 29.3% below the 52-week high and +16% off the 52-week low; a death cross printed 2 sessions ago. Computed from daily closes.

The moving-average stack

Continue: the RYTM chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-11-03

Quick answers

What is the current Closelooknet signal on RYTM?

Downtrend stack — Trades -10.3% vs the 50-day and -10.8% vs the 200-day average, 29.3% below the 52-week high and +16% off the 52-week low; a death cross printed 2 sessions ago. Computed from daily closes. As of 2026-11-03; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is RYTM above its 50-day and 200-day moving averages?

As of 2026-11-03, Rhythm Pharmaceuticals Inc trades -10.3% below its 50-day and -10.8% below its 200-day average, with the 20-day -3.6% away.

How far is RYTM from its 52-week high?

29.3% below the 52-week high and 16% above the 52-week low, as of 2026-11-03.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.